Why A Bristol-Myers Squibb Bid On Celgene Is Plausible

By: via Benzinga
Bristol-Myers Squibb Co (NYSE: BMY)'s rumored interest in acquiring Celgene Corp. (NASDAQ: CELG) sounds plausible, an analyst ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.